Hakim Bouterfa
Overview
Explore the profile of Hakim Bouterfa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
669
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lawal I, Popoola G, Mahapane J, Kaufmann J, Davis C, Ndlovu H, et al.
Biomolecules
. 2020 Dec;
10(12).
PMID: 33287237
People living with human immunodeficiency virus (PLHIV) have excess risk of atherosclerotic cardiovascular disease (ASCVD). Arterial inflammation is the hallmark of atherogenesis and its complications. In this study we aimed...
2.
Nicolas G, Schreiter N, Kaul F, Uiters J, Bouterfa H, Kaufmann J, et al.
J Nucl Med
. 2017 Dec;
59(6):915-921.
PMID: 29191855
Radiolabeled somatostatin (sst) receptor agonists are integral to the diagnosis of gastroenteropancreatic neuroendocrine tumors (NETs), but detection rates, especially of liver metastases, remain limited even with PET/CT. Ga-OPS202 (Ga-NODAGA-JR11; NODAGA...
3.
Nicolas G, Beykan S, Bouterfa H, Kaufmann J, Bauman A, Lassmann M, et al.
J Nucl Med
. 2017 Oct;
59(6):909-914.
PMID: 29025985
Preclinical and preliminary clinical evidence indicates that radiolabeled somatostatin (sst) receptor antagonists perform better than agonists in detecting neuroendocrine tumors (NETs). We performed a prospective phase I/II study to evaluate...
4.
Nicolas G, Mansi R, McDougall L, Kaufmann J, Bouterfa H, Wild D, et al.
J Nucl Med
. 2017 Apr;
58(9):1435-1441.
PMID: 28450554
Radiolabeled somatostatin receptor (SSTR) antagonists have shown in vivo higher uptake in SSTR-expressing tumors than agonists. In this preclinical study, the SSTR2 antagonist OPS201 (DOTA-JR11; DOTA-[Cpa-c(DCys-Aph(Hor)-DAph(Cbm)-Lys-Thr-Cys)-DTyr-NH]) labeled with Lu, Y,...
5.
Beykan S, Dam J, Eberlein U, Kaufmann J, Kjaergaard B, Jodal L, et al.
EJNMMI Res
. 2016 Jun;
6(1):50.
PMID: 27294582
Background: (177)Lu is used in peptide receptor radionuclide therapies for the treatment of neuroendocrine tumors. Based on the recent literature, SST2 antagonists are superior to agonists in tumor uptake. The...
6.
Bushnell Jr D, ODorisio T, ODorisio M, Menda Y, Hicks R, Van Cutsem E, et al.
J Clin Oncol
. 2010 Mar;
28(10):1652-9.
PMID: 20194865
Purpose: Metastatic carcinoid is an incurable malignancy whose symptoms, such as diarrhea and flushing, can be debilitating and occasionally life-threatening. Although symptom relief is available with octreotide, the disease eventually...
7.
Colao A, Cappabianca P, Caron P, De Menis E, Farrall A, Gadelha M, et al.
Clin Endocrinol (Oxf)
. 2009 Jan;
70(5):757-68.
PMID: 19178516
Objective: This prospective randomized study evaluated the efficacy and safety of octreotide LAR vs. surgery in newly diagnosed acromegalic patients. Methods: Totally 104 male and female patients were enrolled in...
8.
Mercado M, Borges F, Bouterfa H, Chang T, Chervin A, Farrall A, et al.
Clin Endocrinol (Oxf)
. 2007 May;
66(6):859-68.
PMID: 17465997
Objective: To evaluate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of acromegaly. Design And Patients: Ninety-eight previously untreated acromegalics were recruited into...
9.
Valkema R, Pauwels S, Kvols L, Barone R, Jamar F, Bakker W, et al.
Semin Nucl Med
. 2006 Mar;
36(2):147-56.
PMID: 16517236
Because the role of chemotherapy, interferon, or somatostatin analogs as antiproliferative agents is uncertain, currently few treatment options exist for patients with metastatic or inoperable gastroenteropancreatic neuroendocrine tumors (GEP-NET). Fifty-eight...
10.
Astruc B, Marbach P, Bouterfa H, Denot C, Safari M, Vitaliti A, et al.
J Clin Pharmacol
. 2005 Jun;
45(7):836-44.
PMID: 15951474
Single-dose pharmacokinetic (PK) profiles and multiple-dose PK modeling were compared for long-acting octreotide (20 or 60 mg) and prolonged-release lanreotide (90 or 120 mg) over 91 days; steady-state profiles were...